Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study

by Alegre, A., Bakker, N.A, Bladé, J., Cavo, M., Larocca, A., Laubach, J., Leleu, X., Maisel, C., Mateos, M.-V, Mazumder, A., Nadeem, O., Oriol, A., Orre, M., Paner, A., Raptis, A., Richardson, P.G, Rodriguez-Otero, P., Sandberg, A., Torrång, A., Touzeau, C.
Published 2022

Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics

by Anderson, L.D., Jr, Beksac, M., Corso, A., Dimopoulos, M., Dürig, J., Engelhardt, M., Galli, M., Grote, L., Jenner, M., Jiang, R., Kanate, A.S, Larocca, A., Liberati, A.M, Lindsay, J., Moreau, P., Oriol, A., Pavic, M., Peluso, T., Richardson, P.G, Robak, P., Rodriguez-Otero, P., Salomo, M., Schjesvold, F., Sonneveld, P., Vural, F., Weisel, K., White, D., Yagci, M.
Published 2022

A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma

by Alegre, A., Arguiñano, J.-M, Bargay, J., Bellón, J.-M, Bladé, J., Blanchard, M.-J, Cabrera, C., de Arriba, F., de la Guía, A.L, de la Rubia, J., Dourdil, V., Encinas, C., García, A., García-Mateo, A., García-Sanz, R., GEM/PETHEMA (Grupo Espanol de Mieloma/Programa para el Estudio de la Terapeutica en Hemopatias Malignas) cooperative study group, Gironella, M., Gonzalez, M.-S, Gonzalez, Y., Granell, M., Hernández, M.-T, Hernandez-Rivas, J., Iñigo, B., Jarque, I., Jímenez-Ubieto, A., Krsnik, I., Lahuerta, J.-J, Martín, J., Martínez-López, J., Mateos, M.-V, Ocio, E.M, Oriol, A., Pérez-Ávila, C.C, Rios, R., Rodríguez-Otero, P., Rosiñol, L., Sampol, A., San-Miguel, J.F, Silvent, M., Soler, J.-A, Sureda, A.
Published 2022